WO2018223836A1 - 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 - Google Patents

一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2018223836A1
WO2018223836A1 PCT/CN2018/087680 CN2018087680W WO2018223836A1 WO 2018223836 A1 WO2018223836 A1 WO 2018223836A1 CN 2018087680 W CN2018087680 W CN 2018087680W WO 2018223836 A1 WO2018223836 A1 WO 2018223836A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
crystalline form
solvent
compound
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/087680
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
黄春香
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Priority to EP18812950.6A priority Critical patent/EP3636655A4/en
Priority to US16/620,115 priority patent/US11136347B2/en
Priority to CN201880035796.0A priority patent/CN110730785B/zh
Publication of WO2018223836A1 publication Critical patent/WO2018223836A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of pharmaceutical crystal technology. Specifically, it relates to a crystalline form of a fatty acid bile acid conjugate, a preparation method thereof and use thereof, and belongs to the field of medicine.
  • Aramchol is a fatty acid bile acid conjugate, specifically an amide conjugate of eicosanoic acid and 3-aminocholic acid.
  • Aramchol is effective in inhibiting the activity of Stearoyl-CoA Desaturase 1, SCD1, which is involved in the regulation of fatty acid metabolism.
  • SCD1 Stearoyl-CoA Desaturase 1
  • Aramchol inhibits SCD1, reduces fatty acid synthesis, and increases ⁇ -oxidation, resulting in an overall reduction in liver storage of triglycerides and fatty acid esters, thereby effectively reducing liver fat content and improving metabolic parameters associated with fatty liver disease.
  • the research and development company is Galmed Pharmaceuticals.
  • Aramchol chemical name is 3 ⁇ -eicosanoylamino-7 ⁇ , 12 ⁇ -dihydroxy-5 ⁇ -cholane-24-carboxylic acid, and its structural formula is represented by formula (I), hereinafter referred to as compound (I):
  • Patent CN100386339C discloses a preparation method of the compound (I), and no other solid form is disclosed.
  • the applicant of the present invention repeats the method of the patent CN100386339C to obtain an amorphous solid (prior art solid), and further studies have found that the amorphous form is obtained.
  • the solid has a high wettability, and the equilibrium weight gain is 2.44% at 80% relative humidity, and the stability is poor.
  • Highly wetted bulk drugs require stringent packaging and storage conditions, resulting in increased production costs of the drug, which is not conducive to production applications.
  • the main object of the present invention is to provide a novel solid form having excellent properties suitable for drug development, and the present invention has been subjected to extensive experimental studies to find the crystal forms CS2, CS3, CS5 and CS8 of the compound (I). They have advantages in at least one of solubility, stability, melting point, wettability, particle size, bioavailability, and processability, purification, fluidity, adhesion, stability in the formulation, and in vitro dissolution, It is worth noting that the crystal form provided by the invention has simple preparation method, lower wettability, uniform particle size and good stability, and provides a better choice for the preparation of the pharmaceutical preparation containing the compound (I). Compound (I) drug development is of great significance.
  • the main object of the present invention is to provide a polymorph having excellent properties of the compound (I), a preparation method and use thereof.
  • the present invention provides a crystal form CS3 of the compound (I) (hereinafter referred to as "crystal form CS3”), and the crystal form CS3 is an anhydride.
  • the X-ray powder diffraction of the crystalline form CS3 has characteristic peaks at diffraction angle 2 ⁇ values of 20.5° ⁇ 0.2°, 15.4° ⁇ 0.2°, and 22.3° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS3 has a characteristic peak at one or two or three points of the diffraction angle 2 ⁇ values of 7.8° ⁇ 0.2°, 17.0° ⁇ 0.2°, and 17.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS3 has characteristic peaks at diffraction angle 2 ⁇ values of 7.8° ⁇ 0.2°, 17.0° ⁇ 0.2°, and 17.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS3 has characteristic peaks at one or two or three points in the diffraction angle 2 ⁇ values of 8.4° ⁇ 0.2°, 5.1° ⁇ 0.2°, and 19.1° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS3 has characteristic peaks at diffraction angle 2 ⁇ values of 8.4° ⁇ 0.2°, 5.1° ⁇ 0.2°, and 19.1° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS3 has a diffraction angle 2 ⁇ of 20.5° ⁇ 0.2°, 15.4° ⁇ 0.2°, 22.3° ⁇ 0.2°, 7.8° ⁇ 0.2°, 17.0° ⁇ 0.2°.
  • a diffraction angle 2 ⁇ 20.5° ⁇ 0.2°, 15.4° ⁇ 0.2°, 22.3° ⁇ 0.2°, 7.8° ⁇ 0.2°, 17.0° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form CS3 is shown in Figure 1A.
  • the present invention also provides a method for preparing the compound (I) crystal form CS3, characterized in that the method comprises:
  • the mixed solvent of the alcohol and water is isopropyl alcohol and water; and the mixed solvent system of the alcohol and the ester is isopropyl alcohol and isopropyl acetate.
  • the halogenated hydrocarbon is chloroform
  • the aromatic hydrocarbon is toluene
  • the ether is tetrahydrofuran or 2-methyltetrahydrofuran
  • the alkane is n-heptane.
  • the crystal form CS3 provided by the present invention has at least one of the following beneficial effects:
  • the crystal form CS3 provided by the present invention has almost no hygroscopicity, and the weight gain of the prior art solid at 80% relative humidity is 2.44%, which has high wettability, and the crystal form CS3 of the present invention.
  • the weight gain at 80% relative humidity is only 0.15%.
  • the low moisture-reducing crystal form can overcome the uncertainty of the weight change of the high-wetting solids due to water absorption, which is beneficial to the long-term storage of the drug, and reduces the material storage and quality control costs.
  • the low moisture-reducing crystal form can also well resist the instability of the crystal form in the process of pharmaceutical preparation and/or storage, and the unprocessability of the preparation caused by external factors such as environmental moisture, and is advantageous for accurate quantification in preparation of the preparation. And later transportation and storage.
  • the crystal form CS3 provided by the present invention has a suitable particle size and good uniformity.
  • the average particle diameter of the crystalline form CS3 is less than 400 ⁇ m.
  • the average particle diameter of the crystalline form CS3 is in the range of less than 200 ⁇ m.
  • the average particle diameter of the crystalline form CS3 is in the range of less than 100 ⁇ m.
  • the crystalline form The average particle diameter of CS3 was 26.3 ⁇ m, and D90 (particle diameter corresponding to 90% of the particle size distribution) was 62.8 ⁇ m, whereas the prior art average particle diameter was 452.5 ⁇ m, and D90 was 870.3 ⁇ m.
  • the crystalline form CS3 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, and is beneficial to the absorption of the drug, thereby improving the bioavailability.
  • the crystalline form CS3 has a narrower particle size distribution than the prior art, and exhibits a monodisperse normal distribution, indicating that the powder of the crystalline form CS3 is uniform.
  • the uniform raw material medicine can be directly applied to the preparation process, avoiding the complicated pretreatment process of the raw material medicine, simplifying the process, reducing the production cost, improving the uniformity of the pharmaceutical preparation, and making the quality of the pharmaceutical preparation more controllable.
  • the crystal form CS3 provided by the present invention has excellent stability and can be stably placed at 25 ° C / 60% relative humidity or / and 40 ° C / 75% relative humidity or / and 60 ° C / 75% relative humidity. For 3 weeks, preferably, it is stable for at least 3 months, preferably at least for 6 months, preferably at least for 1 year. Crystalline CS3 has excellent stability, can ensure that the drug does not undergo crystal transformation during preparation, transportation and storage, and affects the quality of the drug. It is of great significance to ensure the efficacy and safety of the drug and prevent the occurrence of adverse drug reactions.
  • the present invention provides the crystal form CS2 of the compound (I) (hereinafter referred to as "crystal form CS2").
  • the X-ray powder diffraction of the crystal form CS2 has characteristic peaks at diffraction angle 2 ⁇ values of 20.5° ⁇ 0.2°, 16.8° ⁇ 0.2°, and 4.3° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS2 has a characteristic peak at one or two or three points in the diffraction angle 2 ⁇ value of 8.4° ⁇ 0.2°, 17.6° ⁇ 0.2°, and 14.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 has characteristic peaks at diffraction angle 2 ⁇ values of 8.4° ⁇ 0.2°, 17.6° ⁇ 0.2°, and 14.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 has a diffraction angle 2 ⁇ of 20.5° ⁇ 0.2°, 16.8° ⁇ 0.2°, 4.3° ⁇ 0.2°, 8.4° ⁇ 0.2°, and 17.6° ⁇ 0.2°. There are characteristic peaks at one or two or three or four or five or six of 14.9 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of the crystalline form CS2 is as shown in Figure 2A.
  • the crystalline form CS2 has a homogeneous isomorphism.
  • the present invention also provides a process for the preparation of the crystalline form CS2 of the compound (I), characterized in that the method comprises:
  • the crystal form CS2 provided by the present invention has at least one of the following beneficial effects:
  • the crystal form CS2 provided by the invention has lower moisture absorption property, and the weight gain of the prior art solid at 80% relative humidity is 2.44%, which has high wettability, and the crystal of the invention Type CS2 has a weight gain of only 0.46% at 80% relative humidity.
  • the low moisture-reducing crystal form can overcome the uncertainty of the weight change of the water-absorbing material, which is beneficial to the long-term storage of the drug, reducing the material storage and quality control cost; the low moisture-reducing crystal form can also resist the pharmaceutical preparation well. In the process of storage and the like, the crystal form is unstable and the preparation is unprocessable due to external factors such as environmental moisture, which is advantageous for accurate quantification and later transportation and storage in the preparation of the preparation.
  • the crystal form CS2 provided by the present invention has a suitable particle size and good uniformity.
  • the average particle diameter of the crystalline form CS2 is in the range of less than 400 ⁇ m.
  • the average particle diameter of the crystalline form CS2 is in the range of less than 200 ⁇ m.
  • the average particle diameter of the crystalline form CS2 is in the range of less than 100 ⁇ m, in a specific embodiment,
  • the average particle diameter of the crystal form CS2 was 41.9 ⁇ m, and D90 (the particle diameter corresponding to 90% of the particle size distribution) was 87.5 ⁇ m, whereas the prior art average particle diameter was 452.5 ⁇ m, and D90 was 870.3 ⁇ m.
  • the crystalline form CS2 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, and is beneficial to drug absorption, thereby improving bioavailability.
  • the crystalline form CS2 has a narrower particle size distribution than the prior art, and exhibits a monodisperse normal distribution, indicating that the powder of the crystalline form CS2 is uniform.
  • the uniform raw material medicine can be directly applied to the preparation process, avoiding the complicated pretreatment process of the raw material medicine, simplifying the process, reducing the production cost, improving the uniformity of the pharmaceutical preparation, and making the quality of the pharmaceutical preparation more controllable.
  • the crystal form CS2 provided by the present invention has excellent stability and is at least stably placed at 25 ° C / 60% relative humidity or / and 40 ° C / 75% relative humidity or / and 60 ° C / 75% relative humidity. For 3 weeks, preferably, it is stable for at least 3 months, preferably at least for 6 months, preferably at least for 1 year. Crystalline CS2 has excellent stability, can ensure that the drug does not undergo crystal transformation during preparation, transportation and storage, which affects the quality of the drug. It is of great significance to ensure the efficacy and safety of the drug and prevent the occurrence of adverse drug reactions.
  • the present invention provides the crystal form CS5 of the compound (I) (hereinafter referred to as "crystal form CS5").
  • the X-ray powder diffraction of the crystalline form CS5 has characteristic peaks at diffraction angle 2 ⁇ values of 4.8° ⁇ 0.2°, 9.7° ⁇ 0.2°, and 6.4° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS5 is at one or two of the diffraction angle 2 ⁇ values of 20.9° ⁇ 0.2°, 16.8° ⁇ 0.2°, 23.3° ⁇ 0.2°, 14.6° ⁇ 0.2° or There are characteristic peaks at three or four places.
  • the X-ray powder diffraction of the crystalline form CS5 has characteristic peaks at diffraction angle 2 ⁇ values of 20.9° ⁇ 0.2°, 16.8° ⁇ 0.2°, 23.3° ⁇ 0.2°, and 14.6° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS5 has a diffraction angle 2 ⁇ of 4.8° ⁇ 0.2°, 9.7° ⁇ 0.2°, 6.4° ⁇ 0.2°, 20.9° ⁇ 0.2°, and 16.8° ⁇ 0.2°. There are characteristic peaks at one or two or three or four or five or six or seven of 23.3 ° ⁇ 0.2 ° and 14.6 ° ⁇ 0.2 °.
  • Form CS5 is a hydrate having an X-ray powder diffraction pattern as shown in Figure 3A.
  • the present invention also provides a method for preparing the crystalline form CS5, which is prepared by:
  • the solid of the compound (I) is added to an alcohol solvent to prepare a solution containing the compound (I), and acetonitrile is slowly added dropwise to the solution of the compound (I) until a solid appears, and the mixture is further stirred at room temperature, and separated after crystallization. Dry to obtain the crystal form CS5.
  • the alcohol solvent is preferably methanol, ethanol or isopropanol.
  • the crystal form CS5 provided by the present invention has at least one of the following beneficial effects:
  • the crystal form CS5 provided by the invention has lower moisture absorption property, and the weight gain of the prior art solid at 80% relative humidity is 2.44%, which has high wettability, and the crystal of the invention Type CS5 has a weight gain of only 0.35% at 80% relative humidity.
  • the low moisture-reducing crystal form can overcome the uncertainty of the weight change of the water-absorbing material, which is beneficial to the long-term storage of the drug, reducing the material storage and quality control cost; the low moisture-reducing crystal form can also resist the pharmaceutical preparation well. In the process of storage and the like, the crystal form is unstable and the preparation is unprocessable due to external factors such as environmental moisture, which is advantageous for accurate quantification and later transportation and storage in the preparation of the preparation.
  • the crystal form CS5 provided by the present invention has a suitable particle size and good uniformity.
  • the average particle diameter of the crystalline form CS5 is in the range of less than 400 ⁇ m.
  • the average particle diameter of the crystalline form CS5 is in the range of less than 200 ⁇ m.
  • the average particle diameter of the crystalline form CS5 is in the range of less than 100 ⁇ m, in a specific embodiment, The average particle diameter of the crystal form CS5 was 75.6 ⁇ m, whereas the particle size of the prior art was 452.5 ⁇ m.
  • the crystalline form CS5 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, and is beneficial to the absorption of the drug, thereby improving the bioavailability.
  • the crystalline form CS5 has a narrower particle size distribution than the prior art, and exhibits a monodisperse normal distribution, indicating that the powder of the crystalline form CS5 is uniform.
  • the uniform raw material medicine can be directly applied to the preparation process, avoiding the complicated pretreatment process of the raw material medicine, simplifying the process, reducing the production cost, improving the uniformity of the pharmaceutical preparation, and making the quality of the pharmaceutical preparation more controllable.
  • the crystal form CS5 provided by the present invention has excellent stability and is at least stably placed at 25 ° C / 60% relative humidity or / and 40 ° C / 75% relative humidity or / and 60 ° C / 75% relative humidity. For 3 weeks, preferably, it is stable for at least 3 months, preferably at least for 6 months, preferably at least for 1 year.
  • the crystal form CS5 has excellent stability, can ensure that the drug does not undergo crystal transformation during the preparation, transportation and storage process, and affects the quality of the drug, and is of great significance for ensuring the efficacy and safety of the drug and preventing the occurrence of adverse drug reactions.
  • the present invention provides the crystal form CS8 of the compound (I) (hereinafter referred to as "crystal form CS8").
  • the X-ray powder diffraction of the crystalline form CS8 has characteristic peaks at diffraction angle 2 ⁇ values of 6.0° ⁇ 0.2°, 15.5° ⁇ 0.2°, and 20.7° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS8 is at one or two of the diffraction angle 2 ⁇ values of 21.8° ⁇ 0.2°, 9.1° ⁇ 0.2°, 19.9° ⁇ 0.2°, 22.9° ⁇ 0.2° or There are characteristic peaks at three or four places.
  • the X-ray powder diffraction of the crystalline form CS8 has characteristic peaks at diffraction angle 2 ⁇ values of 21.8° ⁇ 0.2°, 9.1° ⁇ 0.2°, 19.9° ⁇ 0.2°, and 22.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS8 has a diffraction angle 2 ⁇ of 6.0° ⁇ 0.2°, 15.5° ⁇ 0.2°, 20.7° ⁇ 0.2°, 21.8° ⁇ 0.2°, and 9.1° ⁇ 0.2°. There are characteristic peaks at one or two or three or four or five or six or seven of 19.9 ° ⁇ 0.2 ° and 22.9 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form CS8 is as shown in Figure 4A.
  • the present invention also provides a method for preparing a crystalline form CS8, the preparation method comprising:
  • the crystal form CS2 is allowed to stand at room temperature for 7 to 30 days, and the obtained sample is heated to 95 ° C ⁇ 2 ° C at a rate of 5 to 20 ° C / min under a nitrogen purge condition, and kept for 1 to 10 minutes, and then 5-20 The temperature CSC was cooled to room temperature to obtain the crystal form CS8.
  • the crystal form CS8 provided by the present invention has at least one of the following beneficial effects:
  • the crystal form CS8 provided by the invention has lower moisture absorbing property, and the weight gain of the prior art solid at 80% relative humidity is 2.44%, which has high moisture absorbing property, and the crystal of the invention
  • the type CS8 has a weight gain of only 0.40% at 80% relative humidity.
  • the low moisture-reducing crystal form can overcome the uncertainty of the weight change of the water-absorbing material, which is beneficial to the long-term storage of the drug, reducing the material storage and quality control cost; the low moisture-reducing crystal form can also resist the pharmaceutical preparation well.
  • the crystal form is unstable and the preparation is unprocessable due to external factors such as environmental moisture, which is advantageous for accurate quantification and later transportation and storage in the preparation of the preparation.
  • the crystal form CS8 provided by the present invention has a suitable particle size and good uniformity.
  • the average particle diameter of the crystalline form CS8 is in the range of less than 400 ⁇ m.
  • the average particle diameter of the crystalline form CS8 is in the range of less than 200 ⁇ m.
  • the average particle diameter of the crystalline form CS8 is in the range of less than 100 ⁇ m.
  • the crystalline form CS8 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, facilitate drug absorption, and thereby improve bioavailability.
  • the crystal form CS8 has a narrower particle size distribution than the prior art, and has a monodisperse normal distribution, indicating that the powder of the crystal form CS8 is uniform.
  • the uniform raw material medicine can be directly applied to the preparation process, avoiding the complicated pretreatment process of the raw material medicine, simplifying the process, reducing the production cost, improving the uniformity of the pharmaceutical preparation, and making the quality of the pharmaceutical preparation more controllable.
  • the crystal form CS8 provided by the present invention has excellent stability and is at least stably placed at 25 ° C / 60% relative humidity or / and 40 ° C / 75% relative humidity or / and 60 ° C / 75% relative humidity. For 3 weeks, preferably, it is stable for at least 3 months, preferably at least for 6 months, preferably at least for 1 year. Crystalline CS8 has excellent stability, which can ensure that the drug does not undergo crystal transformation during preparation, transportation and storage, which affects the quality of the drug. It is of great significance to ensure the efficacy and safety of the drug and prevent the occurrence of adverse drug reactions.
  • the "room temperature” means 25 ° C ⁇ 5 ° C.
  • the “stirring” is carried out by a conventional method in the art, such as magnetic stirring or mechanical stirring, and the stirring speed is 50 to 1800 rpm, wherein the magnetic stirring is preferably 300 to 900 rpm, and the mechanical stirring is preferably 100 to 300 rpm. minute.
  • the “separation” is accomplished using conventional methods in the art, such as centrifugation or filtration.
  • the “centrifugation” operation was carried out by placing the sample to be separated in a centrifuge tube and centrifuging at a rate of 10,000 rpm until the solids all settled to the bottom of the centrifuge tube.
  • the "drying” can be carried out at room temperature or higher. Drying temperatures range from room temperature to about 60 ° C, or to 40 ° C, or to 50 ° C.
  • the drying time can be from 2 to 48 hours, or overnight. Drying is carried out in a fume hood, a forced air oven or a vacuum oven.
  • volatilization is accomplished by conventional methods in the art, such as sealing the container with a sealing film, puncturing the cells, and allowing to stand for volatilization.
  • the "cooling down” is accomplished using conventional methods in the art, such as slow cooling and rapid cooling. Slow cooling is usually carried out at 0.1 ° C / min.
  • the "isomorphic isomorphism” refers to a single-phase crystal in which a substance is partially or completely replaced by other ions or atoms having similar properties in the medium when the substance is crystallized, and is crystallized together. Without changing the crystal structure and bond properties, it only causes a slight change in the unit cell parameters.
  • the XRPD patterns that appear as crystalline forms are the same or similar.
  • crystal or “polymorph” means confirmed by the X-ray diffraction pattern characterization shown.
  • X-ray diffraction pattern will generally vary with the conditions of the instrument. It is particularly important to note that the relative intensities of the X-ray diffraction patterns may also vary with experimental conditions, so the order of peak intensities cannot be the sole or decisive factor. In fact, the relative intensity of the diffraction peaks in the XRPD pattern is related to the preferred orientation of the crystal.
  • the peak intensities shown here are illustrative and not for absolute comparison.
  • the experimental error of the peak angle is usually 5% or less, and errors of these angles should also be taken into account, and an error of ⁇ 0.5°, preferably ⁇ 0.2° is usually allowed.
  • the overall offset of the peak angle is caused, and a certain offset is usually allowed.
  • the same peak position can differ by ⁇ 0.2° and the peak intensity allows for some variability.
  • Any crystal form having a map identical or similar to the characteristic peaks in these maps is within the scope of the present invention.
  • One skilled in the art will be able to compare the maps listed herein with a map of an unknown crystal form to verify whether the two sets of maps reflect the same or different crystal forms.
  • the crystalline forms CS2, CS3, CS5, CS8 of the present invention are pure, unitary, and are substantially free of any other crystalline form.
  • substantially free when used to refer to a new crystalline form means that the crystalline form contains less than 20% by weight of other crystalline forms, especially less than 10% by weight of other crystalline forms, more Other crystal forms of 5% by weight, more preferably less than 1% by weight of other crystal forms.
  • the invention provides a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of the crystalline forms CS2, CS3, CS5, CS8 of the invention, and at least one pharmaceutically acceptable excipient.
  • the present invention provides the use of the crystalline forms CS2, CS3, CS5, CS8 of the compound (I) for the preparation of a pharmaceutical preparation for treating nonalcoholic fatty liver disease or gallstone.
  • the present invention provides the use of the crystalline forms CS2, CS3, CS5, CS8 of the compound (I) for the preparation of a preparation for treating cholesterol type gallstones and atherosclerosis.
  • Figure 1A is an XRPD pattern of a crystalline form CS3 of the present invention.
  • Figure 1B is a TGA diagram of a crystalline form CS3 of the present invention.
  • Figure 1C is a DSC diagram of a crystalline form CS3 of the present invention.
  • Fig. 1D is a 1 H NMR chart of the crystal form CS3 of the present invention.
  • 1E is an XRPD pattern of the crystalline form CS3 of the present invention before and after being placed at 25 ° C / 60% relative humidity for one year.
  • the upper graph is measured before placement, and the lower graph is measured after placement.
  • 1F is an XRPD pattern of the crystalline form CS3 of the present invention before and after being placed at 40 ° C / 75% relative humidity for one year.
  • the upper graph is measured before placement, and the lower graph is measured after placement.
  • Figure 1G is a DVS diagram of a crystalline form CS3 of the present invention.
  • 1H is a superficial XRPD overlay of the crystalline form CS3 before and after the DVS test of the present invention.
  • the upper graph is measured before the wettability test, and the lower graph is measured after the wettability test.
  • Figure 1I is a DVS diagram of a prior art solid.
  • Figure 1J is a PSD diagram of a crystalline form CS3 of the present invention.
  • Figure 1K is a PSD diagram of a prior art solid.
  • 2A is an XRPD pattern of a crystalline form CS2 of the present invention.
  • 2B is a TGA diagram of the crystalline form CS2 of the present invention.
  • 2C is a DSC diagram of the crystalline form CS2 of the present invention.
  • 2D is a superficial XRPD overlay of the crystalline form CS2 before and after the DVS test of the present invention.
  • the upper graph is measured before the wettability test, and the lower graph is measured after the wettability test.
  • 2E is a PSD diagram of a crystalline form CS2 of the present invention.
  • Figure 3A is an XRPD pattern of a crystalline form CS5 of the present invention.
  • Figure 3B is a TGA diagram of the crystalline form CS5 of the present invention.
  • Figure 3C is a DSC diagram of the crystalline form CS5 of the present invention.
  • Figure 3D is a DVS diagram of the crystalline form CS5 of the present invention.
  • 4A is an XRPD pattern of a crystal form CS8 of the present invention.
  • 4B is a TGA diagram of the crystalline form CS8 of the present invention.
  • 4C is a DSC diagram of a crystalline form CS8 of the present invention.
  • 4D is an XRPD pattern of the crystalline form CS8 of the present invention before and after being placed at 60 ° C / 75% relative humidity for three weeks.
  • the upper graph is measured before placement, and the lower graph is measured after placement.
  • 4E is a DVS diagram of the crystal form CS8 of the present invention.
  • 4F is a superficial XRPD overlay of the crystalline form CS8 of the present invention before and after the DVS test.
  • the upper graph is measured before the wettability test, and the lower graph is measured after the wettability test.
  • PSD particle size distribution
  • the X-ray powder diffraction pattern of the present invention was collected on a Bruker D2 PHASER X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the DSC map of the present invention was acquired on a TA Q2000.
  • the method parameters of the DSC according to the present invention are as follows:
  • the TGA maps of the present invention were collected on a TA Instruments Q500.
  • the method parameters of the TGA of the present invention are as follows:
  • 1 H NMR was taken from a Bruker Avance II DMX 400M HZ NMR spectrometer. A sample of 1 to 5 mg was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to prepare a solution of 2 to 10 mg/mL.
  • the particle size distribution results described in the invention were collected on a Microtrac S3500 laser particle size analyzer.
  • the Microtrac S3500 is equipped with an SDC (Sample Delivery Controller) injection system.
  • SDC Sample Delivery Controller
  • This test uses a wet method and the test dispersion medium is Isopar G.
  • the method parameters of the laser particle size analyzer are as follows:
  • the flow rate is 60% of 60% of 65 ml/sec.
  • the compound (I) solid used in the following examples was synthesized according to the preparation method of the prior art (patent CN100386339C).
  • Samples 1-a, 1-b, and 1-c were all tested for Form CS3.
  • the XRPD data of the sample 1-a is shown in FIG. 1A and Table 1B, and the samples 1-b, 1-c have the same or similar XRPD patterns as the sample 1-a.
  • the TGA of Form CS3 is shown in Figure 1B, and when heated to 120 ° C, it has a mass loss gradient of about 0.3%.
  • the DSC of the crystal form CS3 is as shown in Fig. 1C, which has an endothermic peak, and an endothermic peak starts to appear near 111 °C.
  • the crystal form As the most critical active ingredient in the drug, it is important that the crystal form has good physical and chemical stability.
  • the crystal form has good physical stability, ensuring that the bulk drug is not easily converted into other crystal forms during storage and formulation processes, thereby ensuring consistent and controllable sample quality.
  • the wetting weight gain is not less than 15%
  • Humidity Wet weight gain is less than 15% but not less than 2%
  • wetting gain is less than 2% but not less than 0.2%
  • wetting gain is less than 0.2%
  • the crystal form CS3 had an average particle diameter of 26.3 ⁇ m and D90 of 62.8 ⁇ m, whereas the prior art average particle diameter was 452.5 ⁇ m and D90 was 870.3 ⁇ m.
  • the crystalline form CS3 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, and is beneficial to the absorption of the drug, thereby improving the bioavailability.
  • D10 indicates the particle size distribution (volume distribution) accounts for 10% of the particle size
  • D50 indicates the particle diameter corresponding to the particle size distribution (volume distribution), which is also called the median diameter.
  • D90 indicates the particle size distribution (volume distribution) accounts for 90% of the particle size
  • FIGS. 1J and 1K The PSD pattern distribution of the crystalline form CS3 and the prior art solid is shown in FIGS. 1J and 1K.
  • FIG. 1J shows that the crystal form CS3 has a narrow particle size distribution, almost presents a normal distribution, and the particle size distribution is uniform, whereas the prior art solid particles The diameter is large and the uniformity is poor.
  • Samples 2-a to 2-d were all crystalline form CS2 by XRPD detection.
  • the XRPD data of sample 2-a is shown in Fig. 2A and Table 2B, and the samples 2-b to 2-d have the same or similar XRPD patterns as the sample 2-a.
  • the TGA of the crystal form CS2 is as shown in Fig. 2B, and when it is heated to 100 ° C, it has a mass loss gradient of about 2.9% and is a hydrate crystal form.
  • the DSC of the crystal form CS2 is as shown in Fig. 2C, which has an endothermic peak, and an endothermic peak starts to appear near 83 °C.
  • the crystal size distribution of the crystalline form CS2 and CN100386339C of the present invention was measured for 30 seconds, and the particle size distribution was measured. The results are shown in Table 2D.
  • the crystal form CS2 had an average particle diameter of 41.9 ⁇ m and D90 of 87.5 ⁇ m, whereas the prior art average particle diameter was 452.5 ⁇ m and D90 was 870.3 ⁇ m.
  • the crystalline form CS2 has a smaller crystal grain size, can increase the specific surface area of the drug, increase the dissolution rate of the drug, and is beneficial to drug absorption, thereby improving bioavailability.
  • Figs. 2E and 1K The PSD pattern distribution of the crystalline form CS2 and the prior art solid is shown in Figs. 2E and 1K.
  • Fig. 2E shows that the crystal form CS2 has a narrow particle size distribution, almost presents a normal distribution, and the particle size distribution is uniform, whereas the prior art solid particles The diameter is large and the uniformity is poor.
  • the TGA of Form CS5 is shown in Figure 3B, and when heated to 90 ° C, it has a mass loss gradient of about 1.5%.
  • the DSC of the crystal form CS5 is as shown in Fig. 3C, which has an endothermic peak, and an endothermic peak starts to appear near 91 °C.
  • the crystal form CS2 sample was allowed to stand at room temperature for one month, and the obtained sample was heated to 95 ° C at a rate of 10 ° C / min under a nitrogen purge condition, and kept at 95 ° C for 2 min, and cooled at a rate of 5 ° C / min to The obtained sample was allowed to stand at 60 ° C / 75% RH for one month at room temperature.
  • the solid obtained in this example was crystalline form CS8, and its XRPD data is shown in FIG. 4A and Table 4A, and the TGA of the obtained crystalline form CS8 is as shown in FIG. 4B. When heated to 150 ° C, it has a mass loss gradient of about 0.9%.
  • the DSC of the obtained crystalline form CS8 is as shown in Fig. 4C, which has an endothermic peak, and an endothermic peak starts to appear near 104 °C.
  • the crystal form CS2 sample was placed under a humidity condition of 25 ° C / 60% RH for one week, and the obtained sample was heated to 95 ° C at a rate of 10 ° C / min under a nitrogen purge condition, and incubated at 95 ° C for 2 min to 10 The rate of °C/min was lowered to room temperature, and the obtained solid was tested to be crystalline form CS8, and its XRPD is shown in Table 4B.
  • the crystal form As the most critical active ingredient in the drug, it is important that the crystal form has good physical and chemical stability.
  • the crystal form has good physical stability, ensuring that the bulk drug is not easily converted into other crystal forms during storage and formulation processes, thereby ensuring consistent and controllable sample quality.
  • the crystalline form CS8 is stable for at least three weeks at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity, 60 ° C / 75% relative humidity acceleration, preferably at least 3 months, preferably, at least It can be stable for 6 months, preferably, at least for 1 year, indicating that the crystalline form CS8 has good stability and meets the requirements for drug development.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本发明涉及化合物(I)的新晶型及其制备方法和用途。本发明提供的化合物(I)的晶型CS3，晶型CS2，晶型CS5，晶型CS8在溶解度、稳定性、熔点、引湿性、粒径、生物有效性以及加工性能、提纯作用、流动性、黏附性以及制剂中的稳定性和体外溶出等方面中的至少一方面存在优势，为含化合物(I)的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。

Description

一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 技术领域
本发明涉及药物晶体技术领域。具体而言，涉及一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途，属于医药领域。
背景技术
Aramchol是一种脂肪酸胆汁酸偶合物，具体是指二十烷酸和3-氨基胆酸的酰胺偶合物。Aramchol能够有效的抑制与脂肪酸代谢调节有关的硬脂酰辅酶A去饱和酶1(Stearoyl-CoA Desaturase1，SCD1)的活性。Aramchol通过抑制SCD1，降低脂肪酸的合成，同时增加β-氧化，导致甘油三酯和脂肪酸酯肝储存的总体减少，进而有效的降低肝脂肪含量以及改进与脂肪肝病有关的代谢参数，临床上正在被开发用于脂肪肝病和非酒精性脂肪性肝炎，研发公司为Galmed Pharmaceuticals。
Aramchol化学名称为3β-二十烷酰氨基-7α,12α-二羟基-5β-胆烷-24-羧酸，其结构式如式(I)所示，以下简称成化合物(I)：
Figure PCTCN2018087680-appb-000001
专利CN100386339C公开了化合物(I)的制备方法，未见其他任何固体形态的公开，本发明申请人重复专利CN100386339C中方法得到了一种无定形固体(现有技术固体)，进一步研究发现所得无定形固体具有很高的引湿性，80％相对湿度下放置平衡增重2.44％，且稳定性差。高引湿性的原料药对包装和贮存条件要求苛刻，导致药品的生产成本增加，不利于生产应用。为了解决上述问题，本发明主要目的是提供适合于药物开发的具有优异性质的新的固体形态，本发明经过了大量的试验研究，发现了化合物(I)的晶型CS2、CS3、CS5和CS8，它们在溶解度、稳定性、熔点、引湿性、粒径、生物有效性以及加工性能、提纯作用、流动性、黏附性以及制剂中的稳定性和体外溶出等方面中的至少一方面存在优势，值得指出的是本发明提供的晶型制备方法简单，引湿性更低，粒径大小均一，并且具有良好的稳定性，为含化合物(I)的药物制剂的制备提供了更好的选择，对于化合物(I)药物开发具有非常重要的意义。
发明内容
针对现有技术存在的不足，本发明主要目的是提供化合物(I)性质优异的多晶型及其 制备方法和用途。
根据本发明的目的，本发明提供化合物(I)的晶型CS3(以下称作“晶型CS3”)，晶型CS3为无水物。
使用Cu-Kα辐射，所述晶型CS3的X射线粉末衍射在衍射角2θ值为20.5°±0.2°、15.4°±0.2°、22.3°±0.2°处有特征峰。
进一步的，所述晶型CS3的X射线粉末衍射在衍射角2θ值为7.8°±0.2°、17.0°±0.2°、17.9°±0.2°中的一处或两处或三处有特征峰。优选的，所述晶型CS3的X射线粉末衍射在衍射角2θ值为7.8°±0.2°、17.0°±0.2°、17.9°±0.2°处均有特征峰。
进一步的，所述晶型CS3的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、5.1°±0.2°、19.1°±0.2°中的一处或两处或三处有特征峰。优选的，所述晶型CS3的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、5.1°±0.2°、19.1°±0.2°处均有特征峰。
非限制性地，所述晶型CS3的X射线粉末衍射在衍射角2θ值为20.5°±0.2°、15.4°±0.2°、22.3°±0.2°、7.8°±0.2°、17.0°±0.2°、17.9°±0.2°、8.4°±0.2°、5.1°±0.2°、19.1°±0.2°中的一处或二处或三处或四处或五处或六处或七处或八处或九处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS3的X射线粉末衍射谱图如图1A所示。
根据本发明的目的，本发明还提供化合物(I)晶型CS3的制备方法，其特征在于，所述方法包含：
1)将化合物(I)固体加入到醇类与水的混合溶剂或醇类与酯类的混合溶剂体系中配成悬浊液，在0～80℃温度下搅拌得到晶型CS3；
优选的，所述醇类与水的混合溶剂为异丙醇与水；所述醇类与酯类的混合溶剂体系为异丙醇与乙酸异丙酯。
或2)将化合物(I)固体加入到正溶剂中，配成含有化合物(I)的溶液，将反溶剂缓慢滴加到正溶剂溶液中，其中正溶剂为卤代烃类，反溶剂为芳香烃类；或者将正溶剂溶液滴加到反溶剂中，其中正溶剂为醚类，反溶剂为烷烃类，室温搅拌析晶得到晶型CS3；
优选的，所述卤代烃类为氯仿，所述芳香烃类为甲苯，所述醚类为四氢呋喃或者2-甲基四氢呋喃，所述烷烃类为正庚烷。
本发明提供的晶型CS3至少具有一种下述有益效果：
1)与现有技术相比，本发明提供的晶型CS3几乎无引湿性，现有技术固体在80％相对湿度的增重量为2.44％，具有很高的引湿性，而本发明晶型CS3在80％相对湿度的增重量仅为0.15％。低引湿性晶型能够克服高引湿性固体因吸水发生重量变化导致原料晶型组份含量不确定，有利于药品的长期贮存，降低物料储存以及质量控制成本。同时低引湿性晶型也能够很好地对抗药物制剂和/或存储等过程中晶型不稳定以及由环境湿气等外来因素所引起的制剂不可加工等问题，有利于制剂制备中的准确定量和后期的运输和储存。
2)与现有技术相比，本发明提供的晶型CS3粒径大小合适，具有很好的均一性。晶型CS3的平均粒径小于400μm，优选的，晶型CS3的平均粒径在小于200μm范围，优选的，晶型CS3的平均粒径在小于100μm范围，在一个具体的实施例中，晶型CS3的平均粒径为26.3μm，D90(粒径分布中占90％所对应的粒径)为62.8μm，而现有技术平均粒径为 452.5μm，D90为870.3μm。晶型CS3较现有技术具有较小的晶体粒径，可增加药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。且晶型CS3较现有技术具有更窄的粒径分布，呈单分散正态分布，说明晶型CS3的粉体均一性强。均匀的原料药，可以直接应用于制剂工艺中，避免了复杂的原料药前处理过程，简化工艺过程，降低生产成本，提高药物制剂的均一性，使药物制剂的质量更加可控。
3)本发明提供的晶型CS3具有优异的稳定性，在25℃/60％相对湿度或/和40℃/75％相对湿度或/和60℃/75％相对湿度下敞口至少可稳定放置3周，优选的，至少可稳定放置3个月，优选的，至少可稳定放置6个月，优选的，至少可稳定放置1年。晶型CS3具有优异的稳定性，能够保证药品在制备、运输、贮藏过程中不会发生转晶现象而影响到药品质量，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义。
根据本发明的目的，本发明提供化合物(I)的晶型CS2(以下称作“晶型CS2”)。
使用Cu-Kα辐射，所述晶型CS2的X射线粉末衍射在衍射角2θ值为20.5°±0.2°、16.8°±0.2°、4.3°±0.2°处有特征峰。
进一步的，所述晶型CS2的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、17.6°±0.2°、14.9°±0.2°中的一处或两处或三处有特征峰。优选的，所述晶型CS2的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、17.6°±0.2°、14.9°±0.2°处均有特征峰。
非限制性地，所述晶型CS2的X射线粉末衍射在衍射角2θ值为20.5°±0.2°、16.8°±0.2°、4.3°±0.2°、8.4°±0.2°、17.6°±0.2°、14.9°±0.2°中的一处或二处或三处或四处或五处或六处有特征峰。
非限制性地，在本发明的一个具体实施方案中，所述晶型CS2的X射线粉末衍射谱图如图2A所示。非限制性地，晶型CS2存在类质同晶现象。
根据本发明的目的，本发明还提供化合物(I)的晶型CS2的制备方法，其特征在于，所述方法包含：
1)将化合物(I)固体与甲醇单一溶剂或乙醇与丙酮的混合溶剂中混合，溶解后过滤，将滤液放入装有乙腈溶剂的更大装置中，于0～30℃密封静置得到晶型CS2；或2)将化合物(I)固体加入到乙腈溶剂中配成悬浊液，0～30℃温度下搅拌得到晶型CS2。
本发明提供的晶型CS2至少具有一种下述有益效果：
1)与现有技术相比，本发明提供的晶型CS2具有较低的引湿性，现有技术固体在80％相对湿度的增重量为2.44％，具有很高的引湿性，而本发明晶型CS2在80％相对湿度的增重量仅为0.46％。低引湿性晶型能够克服因吸水发生重量变化导致原料晶型组份含量不确定，有利于药品的长期贮存，降低物料储存以及质量控制成本；低引湿性晶型也能够很好地对抗药物制剂和/或存储等过程中晶型不稳定以及由环境湿气等外来因素所引起的制剂不可加工等问题，有利于制剂制备中的准确定量和后期的运输和储存。
2)与现有技术相比，本发明提供的晶型CS2粒径大小合适，具有很好的均一性。晶型CS2的平均粒径在小于400μm范围，优选的，晶型CS2的平均粒径在小于200μm范围，优选的，晶型CS2的平均粒径在小于100μm范围，在一个具体的实施例中，晶型CS2的平均粒径为41.9μm，D90(粒径分布中占90％所对应的粒径)为87.5μm，而现有技术平均粒径为452.5μm，D90为870.3μm。晶型CS2较现有技术具有较小的晶体粒径，可增加 药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。且晶型CS2较现有技术具有更窄的粒径分布，呈单分散正态分布，说明晶型CS2的粉体均一性强。均匀的原料药，可以直接应用于制剂工艺中，避免了复杂的原料药前处理过程，简化工艺过程，降低生产成本，提高药物制剂的均一性，使药物制剂的质量更加可控。
3)本发明提供的晶型CS2具有优异的稳定性，在25℃/60％相对湿度或/和40℃/75％相对湿度或/和60℃/75％相对湿度下敞口至少可稳定放置3周，优选的，至少可稳定放置3个月，优选的，至少可稳定放置6个月，优选的，至少可稳定放置1年。晶型CS2具有优异的稳定性，能够保证药品在制备、运输、贮藏过程中不会发生转晶现象而影响到药品质量，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义。
根据本发明的目的，本发明提供化合物(I)的晶型CS5(以下称作“晶型CS5”)。
使用Cu-Kα辐射，所述晶型CS5的X射线粉末衍射在衍射角2θ值为4.8°±0.2°、9.7°±0.2°、6.4°±0.2°处有特征峰。
进一步的，所述晶型CS5的X射线粉末衍射在衍射角2θ值为20.9°±0.2°、16.8°±0.2°、23.3°±0.2°、14.6°±0.2°中的一处或二处或三处或四处有特征峰。优选的，所述晶型CS5的X射线粉末衍射在衍射角2θ值为20.9°±0.2°、16.8°±0.2°、23.3°±0.2°、14.6°±0.2°处均有特征峰。
非限制性地，所述晶型CS5的X射线粉末衍射在衍射角2θ值为4.8°±0.2°、9.7°±0.2°、6.4°±0.2°、20.9°±0.2°、16.8°±0.2°、23.3°±0.2°、14.6°±0.2°中的一处或二处或三处或四处或五处或六处或七处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS5为水合物，其X射线粉末衍射谱图如图3A所示。
根据本发明的目的，本发明还提供所述晶型CS5的制备方法，所述制备方法为：
将化合物(I)固体加入到醇类溶剂中，配成含有化合物(I)的溶液，将乙腈缓慢滴加到化合物(I)的溶液中，直至出现固体，继续于室温搅拌，析晶后分离干燥获得晶型CS5。
优选的，所述醇类溶剂优选甲醇、乙醇、异丙醇。
本发明提供的晶型CS5至少具有一种下述有益效果：
1)与现有技术相比，本发明提供的晶型CS5具有较低的引湿性，现有技术固体在80％相对湿度的增重量为2.44％，具有很高的引湿性，而本发明晶型CS5在80％相对湿度的增重量仅为0.35％。低引湿性晶型能够克服因吸水发生重量变化导致原料晶型组份含量不确定，有利于药品的长期贮存，降低物料储存以及质量控制成本；低引湿性晶型也能够很好地对抗药物制剂和/或存储等过程中晶型不稳定以及由环境湿气等外来因素所引起的制剂不可加工等问题，有利于制剂制备中的准确定量和后期的运输和储存。
2)与现有技术相比，本发明提供的晶型CS5粒径大小合适，具有很好的均一性。晶型CS5的平均粒径在小于400μm范围，优选的，晶型CS5的平均粒径在小于200μm范围，优选的，晶型CS5的平均粒径在小于100μm范围，在一个具体的实施例中，晶型CS5的平均粒径为75.6μm，而现有技术粒径为452.5μm。晶型CS5较现有技术具有较小的晶体粒径，可增加药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。且晶型CS5较现有技术具有更窄的粒径分布，呈单分散正态分布，说明晶型CS5的粉体均 一性强。均匀的原料药，可以直接应用于制剂工艺中，避免了复杂的原料药前处理过程，简化工艺过程，降低生产成本，提高药物制剂的均一性，使药物制剂的质量更加可控。
3)本发明提供的晶型CS5具有优异的稳定性，在25℃/60％相对湿度或/和40℃/75％相对湿度或/和60℃/75％相对湿度下敞口至少可稳定放置3周，优选的，至少可稳定放置3个月，优选的，至少可稳定放置6个月，优选的，至少可稳定放置1年。晶型CS5具有优异的稳定性，能够保证药品在制备、运输、贮藏过程中不会发生转晶现象而影响到药品质量，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义。
根据本发明的目的，本发明提供化合物(I)的晶型CS8(以下称作“晶型CS8”)。
使用Cu-Kα辐射，所述晶型CS8的X射线粉末衍射在衍射角2θ值为6.0°±0.2°、15.5°±0.2°、20.7°±0.2°处有特征峰。
进一步的，所述晶型CS8的X射线粉末衍射在衍射角2θ值为21.8°±0.2°、9.1°±0.2°、19.9°±0.2°、22.9°±0.2°中的一处或二处或三处或四处有特征峰。优选的，所述晶型CS8的X射线粉末衍射在衍射角2θ值为21.8°±0.2°、9.1°±0.2°、19.9°±0.2°、22.9°±0.2°处均有特征峰。
非限制性地，所述晶型CS8的X射线粉末衍射在衍射角2θ值为6.0°±0.2°、15.5°±0.2°、20.7°±0.2°、21.8°±0.2°、9.1°±0.2°、19.9°±0.2°、22.9°±0.2°中的一处或二处或三处或四处或五处或六处或七处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS8的X射线粉末衍射谱图如图4A所示。
根据本发明的目的，本发明还提供晶型CS8的制备方法，所述制备方法包括：
将晶型CS2于室温条件下放置7～30天，得到的样品在氮气吹扫条件下以5～20℃/min速率升温到95℃±2℃，并保温1～10min，然后以5-20℃/min速率降温到室温得到晶型CS8。
本发明提供的晶型CS8至少具有一种下述有益效果：
1)与现有技术相比，本发明提供的晶型CS8具有较低的引湿性，现有技术固体在80％相对湿度的增重量为2.44％，具有很高的引湿性，而本发明晶型CS8在80％相对湿度的增重量仅为0.40％。低引湿性晶型能够克服因吸水发生重量变化导致原料晶型组份含量不确定，有利于药品的长期贮存，降低物料储存以及质量控制成本；低引湿性晶型也能够很好地对抗药物制剂和/或存储等过程中晶型不稳定以及由环境湿气等外来因素所引起的制剂不可加工等问题，有利于制剂制备中的准确定量和后期的运输和储存。
2)与现有技术相比，本发明提供的晶型CS8粒径大小合适，具有很好的均一性。晶型CS8的平均粒径在小于400μm范围，优选的，晶型CS8的平均粒径在小于200μm范围，优选的，晶型CS8的平均粒径在小于100μm范围。晶型CS8较现有技术具有较小的晶体粒径，可增加药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。晶型CS8较现有技术具有更窄的粒径分布，呈单分散正态分布，说明晶型CS8的粉体均一性强。均匀的原料药，可以直接应用于制剂工艺中，避免了复杂的原料药前处理过程，简化工艺过程，降低生产成本，提高药物制剂的均一性，使药物制剂的质量更加可控。
3)本发明提供的晶型CS8具有优异的稳定性，在25℃/60％相对湿度或/和40℃/75％相对湿度或/和60℃/75％相对湿度下敞口至少可稳定放置3周，优选的，至少可稳定放置3个月，优选的，至少可稳定放置6个月，优选的，至少可稳定放置1年。晶型CS8具有 优异的稳定性，能够保证药品在制备、运输、贮藏过程中不会发生转晶现象而影响到药品质量，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义。
在本发明的晶型的制备方法中：
所述“室温”指25℃±5℃。
所述“搅拌”，采用本领域的常规方法完成，例如磁力搅拌或机械搅拌，搅拌速度为50～1800转/分钟，其中磁力搅拌优选300～900转/分钟，机械搅拌优选100～300转/分钟。
所述“分离”，采用本领域的常规方法完成，例如离心或过滤。“离心”的操作为：将欲分离的样品置于离心管中，以10000转/分钟的速率进行离心，至固体全部沉至离心管底部。
所述“干燥”可以在室温或更高的温度下进行。干燥温度室温～约60℃，或者到40℃，或者到50℃。干燥时间可以为2～48小时，或者过夜。干燥在通风橱、鼓风烘箱或真空烘箱里进行。
所述“挥发”，采用本领域的常规方法完成，例如将容器封上封口膜，扎孔，静置挥发。
所述“降温”，采用本领域的常规方法完成，例如缓慢降温和快速降温。缓慢降温通常以0.1℃/分钟进行。
所述“类质同晶”是指物质结晶时，晶体结构位置上的某些分子的位置部分或全部地被介质中性质相近的其他离子或原子所置换，共同结晶成的单相晶体，而不改变晶体结构化和键性，只引起晶胞参数微小变化的现象。表现为晶型的XRPD图相同或相似。
本发明中，“晶体”或“多晶型”指的是被所示的X射线衍射图表征所证实的。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线衍射图通常会随着仪器的条件而有所改变。特别需要指出的是，X射线衍射图的相对强度也可能随着实验条件的变化而变化，所以峰强度的顺序不能作为唯一或决定性因素。事实上，XRPD图谱中衍射峰的相对强度与晶体的择优取向有关，本文所示的峰强度为说明性而非用于绝对比较。另外，峰角度的实验误差通常在5％或更少，这些角度的误差也应该被考虑进去，通常允许有±0.5°，优选±0.2°的误差。另外，由于样品高度等实验因素的影响，会造成峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线衍射图不必和这里所指的例子中的X射线衍射图完全一致，本文所述“XRPD图相同”并非指绝对相同，相同峰位置可相差±0.2°且峰强度允许一定可变性。任何具有和这些图谱中的特征峰相同或相似的图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的图谱和一个未知晶型的图谱相比较，以证实这两组图谱反映的是相同还是不同的晶型。
在一些实施方案中，本发明的晶型CS2、CS3、CS5、CS8是纯的、单一的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
需要说明的是，本发明中提及的数值及数值范围不应被狭隘地理解为数值或数值范围本身，本领域技术人员应当理解其可以根据具体技术环境的不同，在不背离本发明精神和 原则的基础上围绕具体数值有所浮动，本发明中，这种本领域技术人员可预见的浮动范围多以术语“约”来表示。
此外，本发明提供一种药物组合物，所述药物组合物包含治疗和/或预防有效量的本发明晶型CS2、CS3、CS5、CS8，以及至少一种药学上可接受的赋形剂。
进一步的，本发明提供化合物(I)的晶型CS2、CS3、CS5、CS8在制备治疗非酒精性脂肪肝病或胆结石药物制剂中的用途。
进一步的，本发明提供化合物(I)的晶型CS2、CS3、CS5、CS8在制备治疗胆固醇型胆结石和动脉粥样硬化制剂中的用途。
附图说明
图1A为本发明晶型CS3的XRPD图。
图1B为本发明晶型CS3的TGA图。
图1C为本发明晶型CS3的DSC图。
图1D为本发明晶型CS3的 1HNMR图。
图1E为本发明晶型CS3在25℃/60％相对湿度下放置一年前后的XRPD图，上图为放置前测得，下图为放置后测得。
图1F为本发明晶型CS3在40℃/75％相对湿度下放置一年前后的XRPD图，上图为放置前测得，下图为放置后测得。
图1G为本发明晶型CS3的DVS图。
图1H为本发明晶型CS3的DVS测试前后晶型XRPD叠图，上图为引湿性实验前测得，下图为引湿性实验后测得。
图1I为现有技术固体的DVS图。
图1J为本发明晶型CS3的PSD图。
图1K为现有技术固体的PSD图。
图2A为本发明晶型CS2的XRPD图。
图2B为本发明晶型CS2的TGA图。
图2C为本发明晶型CS2的DSC图。
图2D为本发明晶型CS2的DVS测试前后晶型XRPD叠图，上图为引湿性实验前测得，下图为引湿性实验后测得。
图2E为本发明晶型CS2的PSD图。
图3A为本发明晶型CS5的XRPD图。
图3B为本发明晶型CS5的TGA图。
图3C为本发明晶型CS5的DSC图。
图3D为本发明晶型CS5的DVS图。
图4A为本发明晶型CS8的XRPD图。
图4B为本发明晶型CS8的TGA图。
图4C为本发明晶型CS8的DSC图。
图4D为本发明晶型CS8在60℃/75％相对湿度下放置三周前后的XRPD图，上图为放置前测得，下图为放置后测得。
图4E为本发明晶型CS8的DVS图。
图4F为本发明晶型CS8的DVS测试前后晶型XRPD叠图，上图为引湿性实验前测得，下图为引湿性实验后测得。
具体实施方式
本发明进一步参考以下实施例限定，所述实施例详细描述本发明的晶型的制备和使用方法。对本领域技术人员显而易见的是，对于材料和方法两者的许多改变可在不脱离本发明范围的情况下实施。
采集数据所用的仪器及方法：
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
DVS：动态水分吸附
1HNMR核磁共振氢谱
PSD：粒径分布
本发明所述的X射线粉末衍射图在Bruker D2PHASER X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线反射参数：Cu,Kα
Figure PCTCN2018087680-appb-000002
Kα2/Kα1强度比例：0.50
电压：30仟伏特(kV)
电流：10毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的DSC图在TA Q2000上采集。本发明所述的DSC的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的TGA图在TA Instruments Q500上采集。本发明所述TGA的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
1HNMR采自于Bruker Avance II DMX 400M HZ核磁共振波谱仪。称量1～5mg样品，用0.5mL氘代二甲亚砜溶解，配成2～10mg/mL的溶液。
发明中所述的粒径分布结果是在Microtrac公司的S3500型激光粒度分析仪上采集。Microtrac S3500配备SDC(Sample Delivery Controller)进样系统。本测试采用湿法，测试分散介质为Isopar G。所述的激光粒度分析仪的方法参数如下：
Figure PCTCN2018087680-appb-000003
Figure PCTCN2018087680-appb-000004
*：流速60％为65毫升/秒的60％。
除非特殊说明，以下实施例均在室温条件下操作。
以下实施例中所使用的化合物(I)固体按照现有技术(专利CN100386339C)制备方法合成。
实施例1
晶型CS3的制备例一:
称取一定质量的化合物(I)固体于玻璃小瓶中，加入一定体积的溶剂，如表1A所示，配成悬浮液，在室温下搅拌，离心，干燥，收集固体，将所得固体分别标记为样品1-a、1-b、1-c。
表1A
Figure PCTCN2018087680-appb-000005
经检测，样品1-a、1-b、1-c均为晶型CS3。其中样品1-a的XRPD数据如图1A，表1B所示，样品1-b、1-c与样品1-a具有相同或相似的XRPD图。
表1B
衍射角2θ d值 强度％
5.10 17.31 21.16
5.44 16.24 16.26
6.56 13.47 17.60
7.76 11.40 47.21
8.40 10.52 23.60
10.76 8.22 11.09
11.50 7.70 16.24
11.98 7.39 16.03
12.39 7.14 15.35
12.98 6.82 16.15
13.69 6.47 28.31
14.08 6.29 41.22
15.07 5.88 19.39
15.41 5.75 54.37
15.75 5.63 18.98
16.72 5.30 11.17
17.04 5.20 39.33
17.21 5.15 48.52
17.56 5.05 15.91
17.94 4.94 28.29
18.42 4.82 11.18
18.76 4.73 20.05
19.17 4.63 32.94
20.49 4.33 100.00
21.44 4.14 15.85
22.32 3.98 60.51
22.67 3.92 34.67
23.28 3.82 11.51
23.73 3.75 11.35
24.33 3.66 10.58
25.14 3.54 10.29
25.70 3.47 5.16
26.49 3.36 5.65
晶型CS3的TGA如图1B所示，将其加热至120℃时，具有约0.3％的质量损失梯度。
晶型CS3的DSC如图1C所示，其有一个吸热峰，在111℃附近开始出现吸热峰。
晶型CS3的核磁如图1D所示，核磁数据为： 1HNMR(400MHz,DMSO)δ11.95(s,1H),7.53(d,J＝7.0Hz,1H),4.12(d,J＝3.3Hz,1H),4.05(d,J＝3.2Hz,1H),3.83(s,1H),3.77(s,1H),3.61(s,1H),2.26-1.93(m,6H),1.89-1.03(m,53H),1.04-0.79(m,10H),0.59(s,3H)，并未发现除水以外的其他溶剂峰。
晶型CS3的制备例二：
称15.6mg化合物(I)固体，溶解于0.5mL的氯仿中，过滤，得到滤液，将2.0mL的甲苯滴加上述0.2mL滤液中，搅拌直至出现固体，离心收集固体，干燥，得到样品1-d，经检测，样品1-d为晶型CS3。
晶型CS3的制备例三：
称取一定质量的化合物(I)固体，溶解于表1C中一定体积的正溶剂中，过滤得到滤液，将一定体积的滤液加入表1C体积的反溶剂中，若有固体析出，继续搅拌至有大量固体析出，离心收集固体，干燥，得到样品1-e、1-f；经检测，样品1-e、1-f均为晶型CS3。
表1C
Figure PCTCN2018087680-appb-000006
Figure PCTCN2018087680-appb-000007
晶型CS3稳定性研究：
作为药物中最关键的活性成分，晶型具有良好的物理和化学稳定性至关重要。晶型具有良好的物理稳定性，保证原料药在存储和制剂工艺过程中，不容易转变成其它晶型，从而保证样品的质量一致可控。
取2份晶型CS3样品分别置于25℃/60％相对湿度、40℃/75％相对湿度下敞口放置1年，然后取样测XRPD。结果如表1D所示：
表1D
Figure PCTCN2018087680-appb-000008
结果显示，晶型CS3具有较好的稳定性，符合中国和/或美国《化学药物(原料药和制剂)稳定性研究技术指导原则》要求，适合于药物开发。
晶型CS3的引湿性研究：
取本发明的晶型CS3和CN100386339C固体各约15mg采用动态水分吸附仪测试其引湿性。实验结果如表1E所示。晶型CS3引湿性实验的DVS图如图1G，现有技术固体引湿性实验的DVS图如图1I，结果表明现有技术固体具有很高的引湿性，80％相对湿度增重2.44％，而本发明晶型CS3在80％相对湿度增重0.15％，几乎无引湿性，并且晶型CS3引湿性实验前后晶型也未发生改变，测试前后的XRPD叠图如图1H所示。
表1E
测试样品 80％相对湿度的增重 引湿性界定
CS3 0.15％ 无或几乎无引湿性
CN100386339C固体 2.44％ 有引湿性
关于引湿性特征描述与引湿性增重的界定(中国药典2015年版附录XIX J药物引湿性试验指导原则，实验条件：25℃±1℃，80％相对湿度)：
潮解：吸收足量水分形成液体
极具引湿性：引湿增重不小于15％
有引湿性：引湿增重小于15％但不小于2％
略有引湿性：引湿增重小于2％但不小于0.2％
无或几乎无引湿性：引湿增重小于0.2％
晶型CS3的粒径研究：
取本发明晶型CS3和CN100386339C固体超声30秒后，测试其粒径分布，结果如表1F所示。晶型CS3的平均粒径为26.3μm，D90为62.8μm，而现有技术平均粒径为452.5μm，D90为870.3μm。晶型CS3较现有技术具有较小的晶体粒径，可增加药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。
表1F
Figure PCTCN2018087680-appb-000009
本发明中所用到的缩写的解释如下：
MV：按照体积计算的平均粒径
D10：表示粒径分布中(体积分布)占10％所对应的粒径
D50：表示粒径分布中(体积分布)占50％所对应的粒径，又称中位径
D90：表示粒径分布中(体积分布)占90％所对应的粒径
晶型CS3和现有技术固体的PSD图分布如图1J和1K所示，图1J显示晶型CS3粒径分布较窄，几乎呈现一个正态分布，粒径分布均匀，而现有技术固体粒径较大，且均一性差。
实施例2
晶型CS2的制备例一：
称取一定质量的化合物(I)固体于玻璃小瓶中，加入一定体积表2A中的溶剂溶解过滤后，将装有滤液的玻璃小瓶放入装有5.0mL乙腈溶剂的20mL小瓶中，于室温密封静置析晶得到固体。将所得固体分别标记为样品2-a～2-c。
表2A
样品编号 原料质量(mg) 溶剂(体积比) 溶剂体积(mL)
2-a 32.6 乙醇/丙酮1:1 1.5
2-b 55.9 乙醇/丙酮1:1 2.0
2-c 25.7 甲醇 1.4
晶型CS2的制备例二：
称取约5.3mg的化合物(I)固体于3mL玻璃小瓶中，加入2.0mL的乙腈溶剂形成悬浊液，于室温下搅拌约5天后，离心收集固体，所得固体标记为样品2-d。
经XRPD检测，样品2-a～2-d均为晶型CS2。其中样品2-a的XRPD数据如图2A，表2B所示，样品2-b～2-d与样品2-a具有相同或相似的XRPD图。
表2B
衍射角2θ d值 强度％
2.91 30.32 8.71
4.27 20.70 32.29
4.54 19.48 37.12
5.95 14.86 3.73
8.45 10.47 27.43
8.84 10.00 5.88
10.35 8.54 4.46
12.25 7.22 3.82
14.32 6.18 19.12
14.52 6.10 22.19
14.94 5.93 12.78
16.81 5.27 56.15
17.45 5.08 17.20
17.90 4.96 8.29
20.65 4.30 100.00
20.85 4.26 71.33
23.50 3.79 6.83
25.84 3.45 5.63
28.24 3.16 1.35
32.26 2.78 1.11
34.20 2.62 3.69
34.82 2.58 2.26
晶型CS2的TGA如图2B所示，将其加热至100℃时，具有约2.9％的质量损失梯度，为水合物晶型。
晶型CS2的DSC如图2C所示，其有一个吸热峰，在83℃附近开始出现吸热峰。
晶型CS2的引湿性研究：
取本发明的晶型CS2约10mg采用动态水分吸附仪测试其引湿性。实验结果如表2C所示。引湿性实验前后晶型XRPD如图2D所示。结果表明，本发明的晶型CS2在80％相对湿度下增重0.46％，根据中国药典2015年版附录XIX J药物引湿性试验指导原则，晶型CS2属于略有引湿性，而CN100386339C固体同等条件下增重2.44％(如图1I)，表明本发明的晶型CS2具有更低的引湿性，且晶型CS2引湿性测试前后晶型未发生改变。
表2C
Figure PCTCN2018087680-appb-000010
晶型CS2的粒径研究：
取本发明晶型CS2和CN100386339C固体超声30秒后，测试其粒径分布，结果如表2D所示。晶型CS2的平均粒径为41.9μm，D90为87.5μm，而现有技术平均粒径为452.5μm，D90为870.3μm。晶型CS2较现有技术具有较小的晶体粒径，可增加药物比表面积，提高药物的溶出速率，有利于药物吸收，进而提高生物利用度。
表2D
Figure PCTCN2018087680-appb-000011
晶型CS2和现有技术固体的PSD图分布如图2E和1K所示，图2E显示晶型CS2粒径分布较窄，几乎呈现一个正态分布，粒径分布均匀，而现有技术固体粒径较大，且均一性差。
实施例3
晶型CS5的制备例一:
称取一定质量的化合物(I)固体，溶解于表3A中一定体积的正溶剂中，过滤后，取一定体积的滤液，逐滴加入反溶剂，直至出现固体，继续搅拌至有大量固体析出，离心收集固体，室温下自然干燥后测试。表3A中所得固体分别标记为样品3-a～3-c，经检测，样品3-a～3-c均为晶型CS5。其中样品3-a的XRPD如图3A，表3B所示，样品3-b～2-c与样品3-a具有相同或相似的XRPD图。
表3A
Figure PCTCN2018087680-appb-000012
表3B
衍射角2θ d值 强度％
3.11 28.41 35.83
3.34 26.43 36.32
4.76 18.57 100.00
5.12 17.26 56.39
6.43 13.74 25.69
6.88 12.85 14.22
7.90 11.19 9.13
9.71 9.11 26.62
10.43 8.48 15.50
11.31 7.82 6.40
12.11 7.31 4.84
13.96 6.34 7.31
14.56 6.08 11.44
16.34 5.42 10.45
16.82 5.27 15.50
17.86 4.97 10.06
19.60 4.53 4.80
20.51 4.33 15.06
20.92 4.25 25.84
21.72 4.09 6.44
23.30 3.82 12.46
28.28 3.16 2.88
33.16 2.70 2.22
晶型CS5的TGA如图3B所示，将其加热至90℃时，具有约1.5％的质量损失梯度。
晶型CS5的DSC如图3C所示，其有一个吸热峰，在91℃附近开始出现吸热峰。
晶型CS5的引湿性研究：
取本发明的晶型CS5约8mg采用动态水分吸附仪测试其引湿性。实验结果如表3C所示。引湿性实验的DVS图如图3D。结果表明，本发明的晶型CS5在80％相对湿度下增重0.35％，根据中国药典2015年版附录XIX J药物引湿性试验指导原则，晶型CS5属于略有引湿性，而CN100386339C固体同等条件下增重2.44％(如图1I)，表明本发明的晶型CS5具有更低的引湿性，且晶型CS5引湿性测试前后晶型未发生改变。
表3C
测试样品 80％相对湿度的增重 引湿性界定
晶型CS5 0.35％ 略有引湿性
CN100386339C固体 2.44％ 有引湿性
实施例4
晶型CS8的制备例一：
将晶型CS2样品于室温放置一个月，得到的样品使用TGA在氮气吹扫条件下以10℃/min的速率升温到95℃，并于95℃保温2min，以5℃/min的速率降温到室温，得到的样品于60℃/75％RH放置一月，该实施例所得的固体为晶型CS8，其XRPD数据如图4A，表4A所示，所得晶型CS8的TGA如图4B所示，将其加热至150℃时，具有约0.9％的质量损失梯度。所得晶型CS8的DSC如图4C所示，其有一个吸热峰，在104℃附近开始出现吸热峰。
表4A
衍射角2θ d值 强度％
5.96 14.83 100.00
7.97 11.10 8.80
9.19 9.62 24.41
10.52 8.41 6.32
13.33 6.64 8.28
13.92 6.36 13.11
14.52 6.10 20.11
15.50 5.72 82.15
15.76 5.62 46.17
16.67 5.32 21.95
17.18 5.16 32.62
18.00 4.93 17.41
18.32 4.84 10.15
19.90 4.46 29.70
20.60 4.31 78.93
21.71 4.09 66.13
22.80 3.90 28.42
22.96 3.87 27.23
晶型CS8的制备例二：
将晶型CS2样品于25℃/60％RH湿度条件下放置一周，得到的样品使用TGA在氮气吹扫条件下以10℃/min的速率升温到95℃，并于95℃保温2min，以10℃/min的速率降温到室温，经检测，所得固体为晶型CS8，其XRPD如表4B所示。
表4B
衍射角2θ d值 强度％
4.09 21.62 7.54
5.99 14.75 100.00
8.05 10.99 4.17
9.08 9.74 9.59
10.63 8.32 3.40
14.07 6.29 9.73
14.68 6.03 7.68
15.56 5.69 30.89
15.84 5.60 34.75
16.33 5.43 16.70
16.72 5.30 11.72
17.20 5.16 15.53
17.73 5.00 17.76
19.95 4.45 15.46
20.67 4.30 22.07
21.45 4.14 17.26
21.79 4.08 15.35
22.87 3.89 11.37
晶型CS8的稳定性研究：
作为药物中最关键的活性成分，晶型具有良好的物理和化学稳定性至关重要。晶型具有良好的物理稳定性，保证原料药在存储和制剂工艺过程中，不容易转变成其它晶型，从而保证样品的质量一致可控。
取三份晶型CS8样品分别置于25℃/60％相对湿度、40℃/75％相对湿度、60℃/75％相对湿度下敞口放置三周，然后取样测XRPD。结果显示晶型CS8均未发生变化，代表性的，放置60℃/75％条件下放置三周的稳定性放置前后数据见图4D。
晶型CS8在25℃/60％相对湿度、40℃/75％相对湿度、60℃/75％相对湿度加速条件下至少可稳定三周，优选的，至少可稳定3个月，优选的，至少可稳定6个月，优选的，至少可稳定1年，表明晶型CS8具有较好的稳定性，满足药物开发要求。
晶型CS8的引湿性研究：
取本发明的晶型CS8约7mg采用动态水分吸附仪测试其引湿性。实验结果如表4C所示，引湿性实验的DVS图如图5E。结果表明，本发明的晶型CS8在80％相对湿度的增重量为0.40％，根据中国药典2015年版附录XIX J药物引湿性试验指导原则，晶型CS8属于略有引湿性，而CN100386339C固体同等条件下增重2.44％(如图1I)，表明本发明的晶型CS8具有更低的引湿性，且晶型CS8引湿性测试前后晶型未发生改变，引湿性测试前后的XRPD叠图如图4F所示，上图为DVS前测试所得，下图为DVS后测试所得。
表4C
测试样品 80％相对湿度的增重 引湿性界定
晶型CS8 0.40％ 略有引湿性
CN100386339C固体 2.44％ 有引湿性
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (18)

  1. 一种化合物(I)的晶型CS3，
    Figure PCTCN2018087680-appb-100001
    其特征在于，其X射线粉末衍射图在2θ值为20.5°±0.2°,15.4°±0.2°,22.3°±0.2°处具有特征峰。
  2. 根据权利要求1所述的晶型CS3，其特征在于，其X射线粉末衍射图在2θ值为7.8°±0.2°,17.0°±0.2°,17.9°±0.2°中的一处或两处或三处具有特征峰。
  3. 根据权利要求1或2所述的晶型CS3，其特征在于，其X射线粉末衍射图在2θ值为8.4°±0.2°,5.1°±0.2°,19.1°±0.2°中的一处或两处或三处具有特征峰。
  4. 一种权利要求1中所述晶型CS3的制备方法，其特征在于，所述制备方法包含：
    1)将化合物(I)固体加入到醇类与水的混合溶剂或醇类与酯类的混合溶剂体系中配成悬浊液，在0～80℃温度下搅拌得到晶型CS3；
    或2)将化合物(I)固体加入到正溶剂中，配成含有化合物(I)的正溶剂溶液，将反溶剂缓慢滴加到正溶剂溶液中，其中正溶剂为卤代烃类，反溶剂为芳香烃类；或者将正溶剂溶液滴加到反溶剂中，其中正溶剂为醚类，反溶剂为烷烃类，室温搅拌析晶得到晶型CS3。
  5. 根据权利要求4所述的制备方法，其特征在于：
    方法1)所述醇类与水的混合溶剂为异丙醇与水；所述醇类与酯类的混合溶剂体系为异丙醇与乙酸异丙酯；方法2)中所述卤代烃类为氯仿，所述芳香烃类为甲苯，所述醚类为四氢呋喃或者2-甲基四氢呋喃，所述烷烃类为正庚烷。
  6. 一种化合物(I)的晶型CS2，其特征在于，其X射线粉末衍射图在2θ值为20.5°±0.2°,16.8°±0.2°,4.3°±0.2°处具有特征峰。
  7. 根据权利要求6所述的晶型CS2，其特征在于，其X射线粉末衍射图在2θ值为8.4°±0.2°,17.6°±0.2°,14.9°±0.2°中的一处或两处或三处具有特征峰。
  8. 一种权利要求6中晶型CS2的制备方法，其特征在于，所述制备方法包含：
    1)将化合物(I)固体与甲醇单一溶剂或乙醇与丙酮的混合溶剂混合，溶解后过滤，将滤液放入装有乙腈溶剂的更大装置中，于0～30℃密封静置得到晶型CS2；或2)将化合物(I)固体加入到乙腈溶剂中配成悬浊液，0～30℃温度下搅拌得到晶型CS2。
  9. 一种化合物(I)的晶型CS5，其特征在于，其X射线粉末衍射图在2θ值为4.8°±0.2°,9.7°±0.2°,6.4°±0.2°处具有特征峰。
  10. 根据权利要求9所述的晶型CS5，其特征在于，其X射线粉末衍射图在2θ值为20.9°±0.2°,16.8°±0.2°,23.3°±0.2°,14.6°±0.2°中的一处或二处或三处或四处具有特征峰。
  11. 一种权利要求9中晶型CS5的制备方法，其特征在于，所述方法为：将化合物(I)固体加入到醇类溶剂中，配成含有化合物(I)的溶液，将乙腈缓慢滴加到含化合物(I)的溶液中，直至出现固体，继续于室温搅拌，析晶后分离干燥获得晶型CS5。
  12. 根据权利要求11所述的制备方法，其特征在于：所述醇类溶剂优选甲醇、乙醇、异丙醇。
  13. 一种化合物(I)的晶型CS8，其特征在于，其X射线粉末衍射图在2θ值为6.0°±0.2°,15.5°±0.2°,20.7°±0.2°处有特征峰。
  14. 根据权利要求13所述的晶型CS8，其特征在于，其X射线粉末衍射图在2θ值为21.8°±0.2°,9.1°±0.2°,19.9°±0.2,°22.9°±0.2°中的一处或两处或三处或四处具有特征峰。
  15. 一种权利要求13中晶型CS8的制备方法，其特征在于，所述制备方法为：将晶型CS2于室温条件下放置7～30天，得到的样品在氮气吹扫条件下以5～20℃/min速率升温到95℃±2℃，并保温1～10min，然后以5-20℃/min速率降温到室温得到晶型CS8。
  16. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1所述的晶型CS3、权利要求6所述的晶型CS2、权利要求9所述的晶型CS5、权利要求13所述的晶型CS8中至少一种及其药学上可接受的载体、稀释剂或赋形剂。
  17. 权利要求1所述的晶型CS3、权利要求6所述的晶型CS2、权利要求9所述的晶型CS5、权利要求13所述的晶型CS8或其混合物，在制备治疗非酒精性脂肪肝病或胆结石药物制剂中的用途。
  18. 权利要求1所述的晶型CS3、权利要求6所述的晶型CS2、权利要求9所述的晶型CS5、权利要求13所述的晶型CS8或其混合物，在制备治疗胆固醇型胆结石和动脉粥样硬化制剂中的用途。
PCT/CN2018/087680 2017-06-07 2018-05-21 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 Ceased WO2018223836A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18812950.6A EP3636655A4 (en) 2017-06-07 2018-05-21 CRYSTALLINE FORM OF A FATTY ACID - BILIARY ACID CONJUGATE, PROCESS OF PREPARATION AND APPLICATION
US16/620,115 US11136347B2 (en) 2017-06-07 2018-05-21 Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof
CN201880035796.0A CN110730785B (zh) 2017-06-07 2018-05-21 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710423951.3 2017-06-07
CN201710423951 2017-06-07

Publications (1)

Publication Number Publication Date
WO2018223836A1 true WO2018223836A1 (zh) 2018-12-13

Family

ID=64566106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/087680 Ceased WO2018223836A1 (zh) 2017-06-07 2018-05-21 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途

Country Status (4)

Country Link
US (1) US11136347B2 (zh)
EP (1) EP3636655A4 (zh)
CN (1) CN110730785B (zh)
WO (1) WO2018223836A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296492A (zh) * 1998-04-08 2001-05-23 盖尔梅德国际有限公司 胆汁酸和胆汁酸衍生物的脂肪酸衍生物
CN105848718A (zh) * 2013-12-04 2016-08-10 盖尔梅德研究与发展有限公司 Aramchol盐

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115486B (zh) 2009-12-30 2015-06-03 上海特化医药科技有限公司 一种3-β-花生酰胺基-7α,12α,5β-胆烷-24-羧酸的制备方法
CN106496300B (zh) 2016-10-19 2018-05-18 上海博志研新药物技术有限公司 花生胆酸及其中间体的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296492A (zh) * 1998-04-08 2001-05-23 盖尔梅德国际有限公司 胆汁酸和胆汁酸衍生物的脂肪酸衍生物
CN100386339C (zh) 1998-04-08 2008-05-07 盖尔梅德国际有限公司 胆汁酸和胆汁酸衍生物的脂肪酸衍生物
CN105848718A (zh) * 2013-12-04 2016-08-10 盖尔梅德研究与发展有限公司 Aramchol盐

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3636655A4

Also Published As

Publication number Publication date
CN110730785A (zh) 2020-01-24
CN110730785B (zh) 2022-05-17
EP3636655A4 (en) 2020-08-26
US11136347B2 (en) 2021-10-05
US20210147471A1 (en) 2021-05-20
EP3636655A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
CN114605406B (zh) Amg510化合物的晶型及其制备方法和用途
WO2021244323A1 (zh) 一种乌帕替尼的晶型及其制备方法和用途
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2017215617A1 (zh) 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
KR102221472B1 (ko) 유리 형태의 크리사보롤의 결정 형태 및 그의 제조 방법 및 용도
US20240279265A1 (en) Crystal forms of glucosamine derivative, and preparation method therefor and use thereof
CN110167550A (zh) 西克里维罗甲磺酸盐的固体形式及其制备方法
JP2020500912A (ja) ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
WO2022170864A1 (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
WO2018006870A1 (zh) Galunisertib的晶型及其制备方法和用途
WO2025011259A1 (zh) 瑞司美替罗的晶型及其制备方法和用途
CN104918937A (zh) 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
CN114621212A (zh) Lanifibranor的晶型及其制备方法和用途
WO2018133705A1 (zh) Gft-505的晶型及其制备方法和用途
US20240391933A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
CN110730785B (zh) 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途
WO2018001335A1 (zh) Nbi-98854的晶型及其制备方法和用途
WO2022262841A1 (zh) 一种螺环化合物的盐型、晶型及其制备方法
JP2026506078A (ja) ベンゾアザ芳香環誘導体の塩、結晶形及びその医薬的応用
WO2017016512A1 (zh) 马赛替尼甲磺酸盐的新晶型及其制备方法
WO2015180681A1 (zh) 一种环肽类化合物的组合物及其制备方法和用途
WO2025026050A1 (zh) Bezuclastinib的晶型及其制备方法和用途
CN105859748B (zh) 多环化合物钠盐及其多晶型、制备方法及应用
WO2019105388A1 (zh) 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
WO2018157741A1 (zh) Sb-939的盐的晶型及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18812950

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018812950

Country of ref document: EP

Effective date: 20200107